Mesenchymal stromal cells attenuate primary sjogren's syndrome by modulating PD-1<sup>+</sup>CXCR5<sup>-</sup> T peripheral helper cells via galectin-1.

Stem Cell Res Ther · 2025 · PMC12502370 · PMID 41053875

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

Moreover, Tfh cells showed a decreasing trend at grade four, possibly due to the progression of lesions in later stages.

also in 47,180 other papers

did not reach statistical significanceno p-value reported

There was no significant change in the proportion of Tfh cells, Treg cells, and Tph/Treg in all treatment groups, and the differences between all groups did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Mesenchymal stromal cells attenuate primary sjogren's syndrome by modulating PD-1&lt;sup&gt;+&lt;/sup&gt;CXCR5&lt;sup&gt;-&lt;/sup&gt; T peripheral helper cells via galectin-1.

The sentences

Mesenchymal stromal cells attenuate primary sjogren's syndrome by modulating PD-1<sup>+</sup>CXCR5<sup>-</sup> T peripheral helper cells via galectin-1.